TY - JOUR. T1 - ComparisOn of neointimal coVerage between zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). AU - Kim, Jung Sun. AU - Kim, Byeong Kuk. AU - Jang, Ik Kyung. AU - Shin, Dong Ho. AU - Ko, Young Guk. AU - Choi, Donghoon. AU - Hong, Myeongki. AU - Cho, Yun Kyeong. AU - Nam, Chang Wook. AU - Hur, Seung Ho. AU - Choi, Jin Ho. AU - Song, Young Bin. AU - Hahn, Joo Yong. AU - Choi, Seung Hyuk. AU - Gwon, Hyeon Cheol. AU - Jang, Yangsoo. PY - 2012/4/1. Y1 - 2012/4/1. N2 - Background: Data on strut surface coverage of second-generation drug-eluting stents (DES) are limited. We investigated stent strut coverage of resolute zotarolimus-eluting stent (ZES-R) or everolimus-eluting stent (EES) at 9 months after implantation using optical coherence tomography (OCT). Methods: ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT) is a prospective, randomized, ...

BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO™ Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. The company will also stop the manufacture of CYPHER® and CYPHER SELECT® Plus Sirolimus-Eluting Coronary Stents by the end of 2011.. Due to evolving market dynamics in the drug-eluting stent (DES) business, we see greater opportunities to benefit patients and grow our business in other areas of the cardiovascular device market, said Seth Fischer, Company Group Chair and Worldwide Chairman, Cordis Corporation. Cordis has been a leader in establishing many markets including diagnostic and guiding catheters, bare metal and drug-eluting stents, carotid stenting, and treatment of peripheral vascular disease and arrhythmias. These ...

The PROTECT TRIAL is a randomized stent trial with 8800 patients in approximately 200 hospitals, which is designed to evaluate whether the Endeavor stent PROTECTS against late stent thrombosis resulting in less deaths and myocardial infarctions.. Study Stents:. Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System or next generation model Cordis Cypher® Sirolimus-eluting Coronary Stent, Cordis Cypher Select® Sirolimus-eluting Coronary Stent or next generation model. Primary Objective: To compare overall stent thrombosis rate of the Endeavor® Zotarolimus Eluting Coronary Stent System versus the Cypher® Sirolimus-eluting Coronary Stent in a patient population requiring stent implantation. Secondary Objective: To compare the composite endpoint of total death or cardiac death combined with the number of patients with all non-fatal myocardial infarctions as well as the number of patients with large non-fatal myocardial infarctions for Endeavor® Zotarolimus Eluting Coronary Stent System ...

The long-term safety and efficacy of drug-eluting stent (DES) implantation in the treatment of unprotected left main coronary artery (LMCA) stenosis is still a matter of debate. All consecutive patients (pts) who had sirolimus (SES, Cypher, Cordis, Johnson and Johnson Company, Warren, NJ) or paclitaxel-eluting stent (PES, Taxus, Boston Scientific, Natick, MA) electively implanted in de novo lesions on LMCA between March 2002 and July 2006 were analyzed. A total of 267 patients were treated: 107 with PES and 160 with SES. Sixty-four (23.4%) patients were diabetics, 95 (35.6%) had unstable angina, mean age was 64.5±11.6 years and LVEF 52.2±10.7 %. High mortality risk scores (Euroscore ,6) were present in 84 (31.5%) of the patients. Glycoprotein IIb/IIIa inhibitors were used in 50 (18.7%) patients, 80 (29.9%) underwent intravascular ultrasound. Distal left main lesions were present in 223 (83.5%) of the patients: 209 bifurcations and 14 trifurcations. Both branches were stented in 108 (48.4%) ...

RRISC Trial Reduction of Restenosis In Saphenous vein grafts with Cypher sirolimus-eluting stent Prospective, randomized, double-blind, non industry sponsored, trial comparing sirolimus-eluting stents vs. bare metal stents. Prospective, randomized, double-blind, non industry sponsored, trial comparing sirolimus-eluting stents vs. bare metal stents. 75 patients with 96 lesions localized in 80 diseased saphenous vein grafts were included 75 patients with 96 lesions localized in 80 diseased saphenous vein grafts were included Primary endpoint : in-stent late loss Primary endpoint : in-stent late loss Secondary endpoints: Secondary endpoints:  Clinical events (death, MI, TLR, TVR)  Binary angiographic restenosis in-stent/in-segment  IVUS measured neo-intimal hyperplasia volume

TY - JOUR. T1 - Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population. T2 - A report from the e-SELECT (Multi-center Post-Market Surveillance) registry. AU - Urban, Philip. AU - Abizaid, Alexandre. AU - Banning, Adrian. AU - Bartorelli, Antonio L.. AU - Baux, Ana Cebrian. AU - Davk, Vladimr. AU - Ellis, Stephen. AU - Gao, Runlin. AU - Holmes, David. AU - Jeong, Myung Ho. AU - Legrand, Victor. AU - Neumann, Franz Josef. AU - Nyakern, Maria. AU - Spaulding, Christian. AU - Worthley, Stephen. PY - 2011/3/29. Y1 - 2011/3/29. N2 - Objectives: The aim of this study was to ascertain the 1-year incidence of stent thrombosis (ST) and major bleeding (MB) in a large, unselected population treated with sirolimus-eluting stents (SES). Background: Stent thrombosis and MB are major potential complications of drug-eluting stent implantation. Their relative incidence and predisposing factors among large populations treated ...

TY - JOUR. T1 - Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents. T2 - Three-year results of the RAVEL trial. AU - Fajadet, Jean. AU - Morice, Marie Claude. AU - Bode, Christoph. AU - Barragan, Paul. AU - Serruys, Patrick W.. AU - Wijns, William. AU - Constantini, Constantino R.. AU - Guermonprez, Jean Léon. AU - Eltchaninoff, Hélène. AU - Blanchard, Didier. AU - Bartorelli, Antonio. AU - Laarman, Gert Jan. AU - Perin, MarcoAntonio. AU - Sousa, J. Eduardo. AU - Schuler, Gerhard. AU - Molnar, Ferenc. AU - Guagliumi, Giulio. AU - Colombo, Antonio. AU - Hayashi, Ernesto Ban. AU - Wülfert, Egon. PY - 2005/3/1. Y1 - 2005/3/1. N2 - Background - The use of sirolimus-eluting coronary stents has been associated with a nearly complete elimination of restenosis at 6 months and with a very low 1-year incidence of major adverse cardiac events (MACE). This analysis examined whether these beneficial effects persist over the longer term. Methods and Results - This multicenter ...

TY - JOUR. T1 - The sirolimus-eluting cypher select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis. T2 - Insights from the e-select 64-71 (multicenter post-market surveillance) registry. AU - Abizaid, Alexandre. AU - Costa, J. Ribamar. AU - Banning, Adrian. AU - Bartorelli, Antonio L.. AU - Dzavik, Vladimir. AU - Ellis, Stephen. AU - Gao, Runlin. AU - Holmes, David R.. AU - Jeong, Muyng Ho. AU - Legrand, Victor. AU - Neumann, Franz Josef. AU - Nyakern, Maria. AU - Orlick, Amy. AU - Spaulding, Christian. AU - Worthley, Stephen. AU - Urban, Philip M.. PY - 2012/1/1. Y1 - 2012/1/1. N2 - This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients. There is paucity of consistent data on DES for the treatment of ISR, ...

In 2001, when Morice et al. (1) presented the initial results of RAVEL (The Randomized Study With the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions), showing 0% angiographic restenosis 6 months after implantation of a sirolimus-eluting stent, very few people would have envisaged that more than 10 years later, there would be a need for a trial to evaluate the best treatment strategy for drug-eluting stent (DES) in-stent restenosis (ISR).. Although widespread use of DES (versus bare-metal stents [BMS]), advances in stent design, and greater operator experience have all significantly reduced the incidence of restenosis and resultant target vessel revascularization (2), a low rate of ISR continues to exist and it is not benign. Outcomes are even poorer for those with DES compared with individuals presenting with BMS-ISR (3).. There are several treatment options for DES-ISR (e.g., repeat percutaneous coronary ...

BACKGROUND: There is paucity of data regarding the clinical outcome of second generation drug- eluting stents (DES) post rotational atherectomy (RA) for heavily calcified coronary lesions (HCCL). METHODOLOGY: The study cohort comprised 99 (116 lesions) consecutive patients who underwent RA for HCCL at our institution and received either a first generation DES (40 patients, 53 lesions) or a second generation DES (59 patients, 63 lesions). The analyzed clinical parameters were the 12-month rates of death (all cause and cardiac), Q-wave MI, target lesion revascularization (TLR), definite stent thrombosis (ST) and major adverse cardiac events (MACE) defined as the composite of death, Q-wave MI, or TLR. RESULTS: The two groups were well matched for their baseline characteristics except for a lower left ventricular ejection fraction in the second generation DES group (46.0±23.0% vs. 55.0±9.0%; p=0.02). The group receiving second generation DES had more type C lesions (81.0% vs. 58.8%; p=0.01), ...

Since the drug eluting stents have provided better results concerning restenosis and repeat revascularization comparing to bare metal stents, percutaneous coronary interventions are performing increasingly in more complex stenoses. However, drug eluting stents did not show any advantage on prevention of myocardial infarction and survival. Currently there is no any completed controlled randomized study showing the superiority or equality of drug eluting stents over coronary bypass surgery by means of efficacy and safety. While the long-term results of drug eluting stents still unclear, everyday progressively more patients with multivessel disease are undergoing percutaneous coronary intervention with drug eluting stent implantation. The aim of this review is to discuss the efficacy and safety of drug eluting stents in patients with multivessel disease.. Keywords: Coronary artery disease, stent, drug-eluting stent, multivessel disease, coronary bypass ...

Background: Several recent analyses have suggested that off-label (non-FDA approved) use of drug-eluting stents (DES) is associated with increased adverse events compared with their on-label use. However, it is unknown whether the use of bare metal stents (BMS) is better than use of DES for similar off-label indications.. Methods: We performed a pooled analysis of all registries that included patients who received either a DES or BMS, and provided data on their use for , 1 non-FDA approved indication. We pooled data across studies using random effects models.. Results: A total of 5 registries, which included 21,029 patients, were identified. Among the off-label indications included were STEMI (12.6%), in-stent restenosis (16.0%), vein graft interventions (16.3%), ostial lesions (16.4%) and chronic occlusions (18.2%). The weighted mean duration of follow-up was 15.6 months (range 9 to 36). Compared with BMS, DES were associated with a significant reduction in all-cause mortality (4.6% vs. 8.6, ...

Global Drug-Eluting Stents Market 2025 Report Provides Porters Five Forces Analysis Illustrates the Potency of Buyers & Suppliers Operating in the Industry & the Quantitative Analysis of The Global Market from 2019 to 2025 is Provided to Determine the Market Potential.. Drug eluting stents are tubular mesh-like structures of thin wires that are placed inside coronary arteries during percutaneous coronary interventions (PCIs) to help treat acute myocardial infarction, atherosclerosis, angina pectoris, and other coronary disorders. Presently, a wide range of stents are available in the global drug eluting stents market due to technological advancements leading to their incorporation into stenting technologies. Drug eluting stents are made of metal coated with a pharmacologic agent, which is known to suppress restenosis. These stents have proven to be efficient in the treatment of acute myocardial infraction, angina pectoris, multiple vessel disease, and atherosclerosis. Drug eluting stents have ...

Drug-eluting balloon for in-stent restenosis Yin Chen, Shilian Hu, Lei Wu To the Editor: We read with interest the meta-analysis by Indermuehle A et al which reported that drug-eluting balloon (DEB) appears to show great promise for in-stent restenosis (ISR), and could reduce the risk for major adverse cardiac events (MACE) compared with plain balloon angioplasty (BA)or implantation of drug-eluting stent (DES) in the treatment of ISR (1).Coronary ISR, happened after coronary stent implantation, continued to be a major problem. The authors raised a critical concern assessing the effectiveness of DEB, and long-term outcomes were adequately discussed in the article. Actually, for the PACCOCATH (Treatment of ISR by Paclitaxel Coated PTCA Balloon) trial, the short-term outcomes were not identified in the meta- analysis (2, 3), and the subgroup analysis according to control group (BA or DES) was only adopted for late lumen loss. DEB appears to be more effective in the reduction of binary restenosis ...

With Habib Samady, MD, and John Wang, MD, MSc. In this edition of our Conversations with Experts series, Habib Samady, MD, director of interventional cardiology and the cardiac catheterization laboratory at Emory University Hospital in Atlanta, speaks with John Wang, MD, MSc, chief of the cardiac catheterization laboratory at MedStar Union Memorial Hospital in Baltimore, about the current and future role of bare-metal stents in the interventional cardiology landscape. Dr. Wang was the national principal investigator of the OMEGA trial, the results from which led to the FDA approval of the REBEL™ Platinum Chromium Coronary Stent System (Boston Scientific Corporation; Natick, Massachusetts).. John Wang, MD, MSc: Dr. Samady, let me first ask you: what percentage of the time do you use drug-eluting stents versus bare-metal stents in your practice? Habib Samady, MD: At Emory University Hospital, we probably use drug-eluting stents 85% of the time and bare-metal stents 15% of the time. Dr. Wang: ...

A prospective multicenter registry in real-world Japanese patients undergoing DAPT for three months after stenting. To assess the long-term safety of Endeavor Zotarolimus-eluting stent through noninferiority in the primary endpoint between two different continuous regimen (three and twelve months) groups of DAPT after stenting with Endeavor Zotarolimus-eluting stent in real-world Japanese patients and to examine the optimal duration of DAPT after stenting with Endeavor Zotarolimus-eluting stent. The long-term DAPT group in the present clinical study (to be appropriated from the post-marketing surveillance of Endeavor) should consist of consecutive patients undergoing DAPT for twelve months after stenting, while the short-term DAPT group (to be newly registered in the present clinical study) should consist of patients who are instructed to undergo DAPT for three months after stenting ...

A Prospective Randomized Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS element) for the Treatment of up to Two De Novo Coronary Artery Lesions - PLATINUM Trial

TY - JOUR. T1 - Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation a randomized, controlled trial. AU - Lee, Cheol Whan. AU - Ahn, Jung Min. AU - Park, Duk Woo. AU - Kang, Soo Jin. AU - Lee, Seung Whan. AU - Kim, Young Hak. AU - Park, Seong Wook. AU - Han, Seungbong. AU - Lee, Sang Gon. AU - Seong, In Whan. AU - Rha, Seung Woon. AU - Jeong, Myung Ho. AU - Lim, Do Sun. AU - Yoon, Jung Han. AU - Hur, Seung Ho. AU - Choi, Yun Seok. AU - Yang, Joo Young. AU - Lee, Nae Hee. AU - Kim, Hyun Sook. AU - Lee, Bong Ki. AU - Kim, Kee Sik. AU - Lee, Seung Uk. AU - Chae, Jei Keon. AU - Cheong, Sang Sig. AU - Suh, Il Woo. AU - Park, Hun Sik. AU - Nah, Deuk Young. AU - Jeon, Doo Soo. AU - Seung, Ki Bae. AU - Lee, Keun. AU - Jang, Jae Sik. AU - Park, Seung Jung. PY - 2014/1/21. Y1 - 2014/1/21. N2 - Background-The risks and benefits of long-term dual antiplatelet therapy remain unclear. Methods and Results-This prospective, multicenter, open-label, randomized comparison trial was ...

In the first-in-human study, 50 patients with in-stent restenosis (following either a drug-eluting stent or bare metal stent) underwent coronary angioplasty with the Virtue balloon. The primary safety endpoint was the 30-day rate of target lesion failure-a composite of cardiac death, target vessel myocardial infarction, and clinically-driven target lesion revascularisation-and the primary performance endpoint was in-stent late lumen loss at six months.. Results. Verheye et al comment: No target lesion failures were reported through the 30-day follow-up for the entire 50 patient study population. Among the 49 intention-to-treat patients at the six month follow-up, one underwent coronary artery bypass and four received target lesion revascularisation for a target lesion failure rate of 8.2% and major adverse cardiac event rate of 10.2%. They add that in-segment late lumen loss was 0.31±0.52mm which met the established criteria for superiority to historical plain balloon angioplasty values ...

To the Editor:. There are questions regarding long-term safety of drug-eluting stents (DES), especially concern about an increased rate of late DES thrombosis compared with bare-metal stents. Numerous intravascular ultrasound (IVUS) studies have reported an increased frequency of late stent malapposition (LSM) in patients with DES (1-3), speculating that there may be a relationship between LSM and late stent thrombosis. The present study reports the long-term (,2 years) follow-up after the diagnosis of LSM was made using serial IVUS examination after DES implantation.. We previously reported 82 patients (85 lesions) with LSM from an overall cohort of 557 patients (705 native lesions) who underwent DES implantation (mean interval between baseline and follow-up IVUS of 6.1 ± 2.1 months). No intervention was performed in 542 patients (683 lesions) at 6-month follow-up (3). At least 2-year follow-up was available for all but 10 patients (12 lesions). Therefore, the present study reports 532 ...

The appraisal committee considered the evidence on the clinical effectiveness of DES in the treatment of coronary heart disease (CHD). The meta-analysis of the clinical trials, conducted by the assessment group,3 showed that the use of DES reduced the rate of revascularisation in the target lesions and the target vessels, at all follow-up time points up to three years, compared with bare-metal stents (BMS). This reduced rate of revascularisation was not, however, accompanied by a reduction in mortality. The committee additionally took into account the ongoing international debate regarding the possible adverse effects of DES on the longer-term risks of myocardial infarction and mortality. It accepted the findings of the Food and Drug Administration review4 and agreed that the most reasonable view at present is that DES conferred no statistically significant benefits or harms in mortality or acute myocardial infarction (MI) rates in the longer term over BMS, when used within their indications for ...

Results from the PRISON IV Trial Presented at TCT 2016 and Simultaneously Published in JACC: Cardiovascular Interventions. WASHINGTON - November 2, 2016 - Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin strut sirolimus-eluting stents (Osiro SES) with a biodegradable polymer compared to thin-strut everolimus-eluting stents (Xience EES) with a durable polymer in terms of in-segment late lumen loss in successfully treated chronic total occlusions. In addition, although the rate of binary restenosis was low overall in this complex lesion subset, it was higher with the Osirio SES compared with the Xience EES.. Findings from the PRISON IV trial were reported today at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the worlds premier educational meeting specializing in interventional cardiovascular medicine. The study was also published in the ...

The Academic Research Consortium (ARC) divides stent thrombosis (ST) into early (within 30 days), late (30 days to 1 year), and very late (beyond 1 year). Intravascular imaging studies, to date mostly using intravascular ultrasound (IVUS), have provided clues with regard to the causes of ST-primarily by focusing on either early or very late ST, although each study usually includes a small number of patients with events between 30 days and 1 year. In this issue of JACC: Cardiovascular Interventions, the current study is similar in that 15 of 18 patients have very late ST with only 3 patients presenting earlier than 1 year (and those 3 at least 172 days) after implantation (1).. The distinction between patients with early versus very late ST is important, especially after drug-eluting stent (DES) implantation. Studies should not combine these 2 groups of patients, because their fundamental mechanisms seem to be different.. The IVUS-identified causes or predictors of early ST are mechanical and ...

Spearheaded by principal investigator Stéphane Cook, MD, University and Hospital Fribourg, Switzerland, the trial sought to assess the efficiency and safety of the Absorb bioresorbable vascular scaffold and its ability to reduce long-term complications such as neoatherosclerosis and very late stent thrombosis. Testing the device against the EES and BES, the trial divided its study population into respective treatment groups (BVS, n=78; EES, n=80; BES, n=80).. Clinical outcomes at nine months showed that the BVS arm experienced nine device-oriented major adverse cardiac events, while the EES and BES arms had 11 and four respectively. Results also showed the BVS arm experienced 21 patient-oriented major adverse cardiac events (all-cause mortality, myocardial infarction, revascularization, target vessel revascularization), while EES and BES had 26 and 15 respectively. Cook and colleagues note that in-segment LLL was slightly but significantly higher in BVS compared to EES/BES, and that a possible ...

Background: It is important to determine the best drug-eluting stent (DES) for acute myocardial infarction (AMI) in patients with renal impairment. In this studythe outcomes of everolimus-eluting stents (EESs), zotarolimus-eluting stents (ZESs) and biolimus-eluting stents (BESs) were evaluated.. Methods: From the Korea Acute Myocardial Infarction-National Institutes of Health registry, a total of 1,470 AMI patients with renal impairment undergoing percutaneous coronary intervention (PCI) were enrolled (816 with EES, 345 with ZES, and 309 with BES). Renal impairment was defined as creatinine clearance , 60 mL/min/1.73 m2 estimated by the Cockcroft-Gault method. Major adverse cardiac and cerebrovascular events were determined as the composite of all-cause death, non-fatal myocardial infarction (MI), cerebrovascular accident, any revascularization, rehospitalization and stent thrombosis. All clinical outcomes were analyzed.. Results: The baseline characteristics of the patients revealed no ...

OBJECTIVES: To compare the efficacy and safety of drugeluting stents (DES) vs. bare-metal stents (BMS) in patients with acute ST-segment-elevation myocardial infarction (STEMI). BACKGROUND: DES effectively reduce restenosis in elective percutaneous c

This head-to-head trial will assess the non-inferiority of NEVO sirolimus-eluting stent to the XIENCE V everolimus-eluting stent for the prevention of coronary

Patients with diabetes mellitus have less favourable outcomes after percutaneous coronary intervention (PCI) than non-diabetics. We performed a subgroup analysis of the multicentre RAVEL trial to examine the impact of the sirolimus-eluting stent (SES) on outcomes in diabetic patients. The RAVEL study randomized 238 patients to treatment with either sirolimus-eluting or bare metal stents. Forty-four patients were diabetic; 19 received sirolimus-eluting stents and 25 were treated with bare metal stents. The differences in outcomes between diabetic and non-diabetic patients treated with SES (n=101) were also assessed. Follow-up angiography was performed at 6 months. Major adverse cardiac events (MACE) defined as death, myocardial infarction (MI), or target lesion revascularization (TLR) were analysed at 12-month follow-up. Six-month in-stent late lumen loss was significantly lower for the diabetic SES than the bare stent group (0.07+/-0.2 vs 0.82+/-0.5mm; P,0.001) and similar to that in ...

TY - JOUR. T1 - Impact of angiographic residual stenosis on clinical outcomes after new-generation drug-eluting stents implantation. T2 - Insights from a pooled analysis of the RESET and NEXT trials. AU - RESET and NEXT Investigators. AU - Watanabe, Hiroki. AU - Morimoto, Takeshi. AU - Shiomi, Hiroki. AU - Natsuaki, Masahiro. AU - Kawai, Kazuya. AU - Kozuma, Ken. AU - Igarashi, Keiichi. AU - Kadota, Kazushige. AU - Tanabe, Kengo. AU - Morino, Yoshihiro. AU - Hibi, Kiyoshi. AU - Akasaka, Takashi. AU - Abe, Mitsuru. AU - Suwa, Satoru. AU - Muramatsu, Toshiya. AU - Kobayashi, Masakazu. AU - Dai, Kazuoki. AU - Nakao, Koichi. AU - Tarutani, Yasuhiro. AU - Fujii, Kenshi. AU - Kimura, Takeshi. N1 - Funding Information: The RESET study was supported by Abbott Vascular Japan, and the NEXT study was supported by Terumo. Publisher Copyright: © 2018 The Authors.. PY - 2018/7/1. Y1 - 2018/7/1. N2 - Background-Previous intravascular ultrasound studies suggested the association of stent underexpansion with ...

In patients with left main coronary artery disease and low or intermediate SYNTAX scores by site assessment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite end point of death, stroke, or myocardial infarction at 3 years. (Funded by Abbott Vascula …

This head-to-head noninferiority trial is comparing the efficacy and tolerability of a platinum chromium everolimus-eluting coronary stent system [PROMUS

PRACTICAL RECOMMENDATIONS ON ANTI-THROMBOTIC TREATMENT IN PATIENTS TREATED WITH DRUG-ELUTING STENTS. Giuseppe Biondi-Zoccai Ospedale S. Giovanni Battista

Approximately 70 percent of angioplasty procedures also involve stenting, which is the insertion of a small metal cylinder called a stent into a blood vessel. In this procedure, a collapsed stent is placed over the balloon at the tip of the catheter. When the balloon inflates, the stent pops open and reinforces the artery walls. The balloon and catheter are then withdrawn and the stent remains permanently. In a few weeks, tissue from the artery lining grows over the stent.. There are two types of stents. Bare-metal stents are plain, untreated metal cylinders. Drug-eluting stents (also called drug-coated stents) are coated with medication before they are placed in the artery. This medication helps prevent scarring and lowers the risk for restenosis (re-narrowing of the artery). Drug-eluting stents may present a higher risk for blood clot formation than bare-metal stents. ...

Pubmed.ncbi.nlm.nih.gov DA: 23 PA: 10 MOZ Rank: 47. Objectives: This study sought to report the final 5-year outcomes of the ENDEAVOR IV (A Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) trial comparing the Endeavor zotarolimus-eluting stent (E-ZES) (Medtronic, Santa Rosa, California) with … ...

The optimal revascularization strategy of coronary artery bypass grafting (CABG) versus percutaneous coronary intervention with drug-eluting stent (PCI-DES) in patients with chronic kidney disease (CKD) and multivessel disease (MVD) remains unclear.. ...

The main findings of this single-center study are: 1) there was still no difference at a median of 61.9 months (IQR: 57.8 to 67.2 months) in the occurrence of MACCE between elective PCI with DES implantation and CABG for ULMCA disease; 2) the benefit of PCI in the composite end point of cardiac death, MI, and cerebrovascular events that we reported at 1 year was still present at a longer term clinical follow-up; and 3) the advantage of CABG was confirmed in the lower need for repeated revascularization. According to current guidelines, the treatment of ULMCA disease with PCI has a Class IIb indication (1). Some retrospective studies evaluating surgical treatment for this disease reported an in-hospital mortality rate varying from 1.7% to 7.0% and a 1-year mortality rate of 6% to 14% (18-21).. Encouraging 1-year and more recently 3-year results have been reported for PCI with DES implantation in this particular subset of patients (2-11). Observational, nonrandomized registries (5,13,16) reported ...

The drug-eluting balloon (DEB) is a device that is used to reduce the risk of repeat stent implantation in patients with in-stent restenosis (ISR) (1). Characterization of tissue by optical coherence tomography (OCT) may provide useful information to identify good candidates for DEBs (2). However, the image visualized by OCT just after DEB dilation is unclear. We present images after DEB dilation visualized by OCT.. A 45-year-old man was treated with a bare metal stent (BMS) (S-stent 4.0/23.0 mm) implanted in the right coronary artery (RCA) for acute ST-segment elevation myocardial infarction. After percutaneous coronary intervention (PCI), he was taking 100 mg of aspirin and 75 mg of clopidogrel. However, a second coronary angiography at 6 months after BMS implantation showed ISR in the BMS. A repeat PCI was performed for ISR in the RCA. After the guide wire was advanced to the distal portion of the RCA, the target lesion was dilated using a 4.0/13.0 mm scoring balloon catheter (Lacrosse ...

TY - JOUR. T1 - 10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents. AU - Galløe, Anders M. AU - Kelbæk, Henning. AU - Thuesen, Leif. AU - Hansen, Henrik S.. AU - Ravkilde, Jan. AU - Hansen, Peter R. AU - Christiansen, Evald H. AU - Abildgaard, Ulrik. AU - Stephansen, Ghita. AU - Lassen, Jens F. AU - Engstrøm, Thomas. AU - Jensen, Jan Skov. AU - Jeppesen, Jørgen L. AU - Bligaard, Niels. AU - SORT OUT II Investigators. N1 - Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.. PY - 2017/2/14. Y1 - 2017/2/14. KW - Journal Article. U2 - 10.1016/j.jacc.2016.11.055. DO - 10.1016/j.jacc.2016.11.055. M3 - Journal article. C2 - 28183505. VL - 69. SP - 616. EP - 624. JO - Journal of the American College of Cardiology. JF - Journal of the American College of Cardiology. SN - 0735-1097. IS - 6. ER - ...

But OCT allows viewing the interior surfaces of the artery and stent in an awake patient. The imaging is done in the cath lab, over the same type of wire as balloons, stents, IVUS, etc. devices are delivered.. The assessment of strut coverage in stents was the goal of the ODESSA Trial (Optical coherence tomography for DES SAfety). Presented last Tuesday by Dr. Giulio Guagliumi of Ospedali Riuniti di Bergamo, Italy, the goal of this trial was to determine whether OCT could accurately measure strut coverage and stent malapposition in long lesions (greater than 20mm) that required overlapping stents. Overlapping stents are associated with an increased incidence of uncovered struts. Although the number of patients (77) and stents (189) was small, the actual number of struts analyzed was 53,047. The stents were further divided in to four groups: sirolimus-eluting (SES) or CYPHER stents, paclitaxel-eluting (PES) or TAXUS stents, zotarolimus-eluting (ZES) or ENDEAVOR stents, and bare-metal stents ...

TY - JOUR. T1 - Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease. T2 - Twelve-month zilver PTX randomized study results. AU - Dake, Michael D.. AU - Ansel, Gary M.. AU - Jaff, Michael R.. AU - Ohki, Takao. AU - Saxon, Richard R.. AU - Smouse, H. Bob. AU - Zeller, Thomas. AU - Roubin, Gary S.. AU - Burket, Mark W.. AU - Khatib, Yazan. AU - Snyder, Scott A.. AU - Ragheb, Anthony O.. AU - White, J. King. AU - Machan, Lindsay S.. N1 - Copyright: Copyright 2012 Elsevier B.V., All rights reserved.. PY - 2011/10. Y1 - 2011/10. N2 - Background-Sustained benefits of drug-eluting stents in femoropopliteal arteries have not been demonstrated. This prospective, multinational, randomized study was designed to compare the 12-month safety and effectiveness of a polymer-free, paclitaxel-coated nitinol drug-eluting stent (DES) with percutaneous transluminal angioplasty (PTA) and provisional bare metal stent (BMS) placement in patients with ...

Treatment options for patients with left main coronary artery disease.. Rev Cardiovasc Med. 2011;12(2):e77-83. Authors: Lee MS, Nguyen J. Coronary artery bypass grafting (CABG) is the gold standard for the treatment of left main disease, whereas percutaneous coronary intervention is a viable option for patients who are candidates for revascularization but ineligible for CABG. CABG is limited by extended hospital stay followed by rehabilitation and mediocre long-term patency of saphenous vein grafts. Drug-eluting stents decrease the restenosis rates compared with bare metal stents and provide comparable clinical outcomes with those of CABG. Patients with isolated left main disease limited to the ostium or midbody are most likely to have good clinical outcomes with low restenosis and stent thrombosis rates. The results of the ongoing EXCEL trial, which compares left main percutaneous coronary intervention with drug-eluting stents and CABG, will provide insight regarding the ideal revascularization ...

TY - JOUR. T1 - Chronic Arterial Responses to Polymer-Controlled Paclitaxel-Eluting Stents. T2 - Comparison with Bare Metal Stents by Serial Intravascular Ultrasound Analyses: Data from the Randomized TAXUS-II Trial. AU - Tanabe, Kengo. AU - Serruys, Patrick W.. AU - Degertekin, Muzaffer. AU - Guagliumi, Giulio. AU - Grube, Eberhard. AU - Chan, Charles. AU - Munzel, Thomas. AU - Belardi, Jorge. AU - Ruzyllo, Witold. AU - Bilodeau, Luc. AU - Kelbaek, Henning. AU - Ormiston, John. AU - Dawkins, Keith. AU - Roy, Louis. AU - Strauss, Bradley H.. AU - Disco, Clemens. AU - Koglin, Jörg. AU - Russell, Mary E.. AU - Colombo, Antonio. PY - 2004/1/20. Y1 - 2004/1/20. N2 - Background-Polymer-controlled paclitaxel-eluting stents have shown a pronounced reduction in neointimal hyperplasia compared with bare metal stents (BMS). The aim of this substudy was to evaluate local arterial responses through the use of serial quantitative intravascular ultrasound (IVUS) analyses in the TAXUS II trial. Methods and ...

OBJECTIVES: We used optical coherence tomography, which has a resolution of |20 microm, to analyze thin layers of neointima in rapamycin-eluting coronary stents. BACKGROUND: Lack of neointimal coverage has been implicated in the pathogenesis of drug-eluting coronary stent thrombosis. Angiography and intracoronary ultrasound lack the resolution to examine this. METHODS: We conducted a randomized trial in patients receiving polymer-coated rapamycin-eluting stents (Cypher, Cordis, Johnson & Johnson, Miami, Florida) and nonpolymer rapamycin-eluting stents (Yukon, Translumina, Hechingen, Germany) to examine neointimal thickness, stent strut coverage, and protrusion at 90 days. Twenty-four patients (n = 12 for each group) underwent stent deployment and invasive follow-up at 90 days with optical coherence tomography. The primary end point was binary stent strut coverage. Coprimary end points were neointimal thickness and stent strut luminal protrusion. RESULTS: No patient had angiographic restenosis. For

BACKGROUND: Adverse cardiac event rates are higher for percutaneous coronary intervention (PCI) of bifurcation lesions. Currently, provisional stenting or a simple stenting strategy is the standard treatment for bifurcated lesions, but its performance remains limited because of a risk of side-branch (SB) closure and a higher rate of target lesion revascularization (TLR). We report a new provisional side-branch stenting strategy to treat coronary bifurcation lesions using a balloon-stent kissing technique (BSKT).. METHODS: From January 2011 to December 2012, a total of 60 patients with 60 bifurcation lesions underwent PCI using BSKT. Baseline and postprocedural quantitative coronary angiography (QCA) analyses were performed. Procedural and immediate clinical outcomes were reviewed.. RESULTS: The majority of patients presented with acute coronary syndrome (98%) and had true bifurcation lesions (98%). TIMI-3 flow was established in 100% of the main branch and SB lesions. QCA revealed preservation ...

EU5 Non-Vascular Stents Market Outlook to 2020 is a new market research publication announced by Reportstack. This report provides key market data on the EU5 Non-Vascular Stents market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Biliary Stents (Plastic Biliary Stents and Metal Biliary Stents (Metal Non-Covered Biliary Stents, Metal Partially Covered Biliary Stents and Metal Fully Covered Biliary Stents)), Gastrointestinal Stents (Fully Covered, Partially Covered and Non-Covered Gastrointestinal Stents), Airway Stents (Silicone Airway Stents and Metallic Airway Stents (Fully Covered and Uncovered Metallic Airway Stents) and Urinary Tract Stents ((Ureteral Stents (Metal, Polymer and Bioabsorbable Ureteral Stents), Prostate Stents (Metal, Polymer and Bioabsorbable Prostate Stents) and Urethral Stents (Metal, Polymer and Bioabsorbable Urethral Stents ...

Fingerprint Dive into the research topics of Stent thrombosis with bioabsorbable polymer drug-eluting stents: insights from the Food and Drug Administration database. Together they form a unique fingerprint. ...

TY - JOUR. T1 - Drug-eluting balloon versus second generation drug eluting stents in the treatment of in-stent restenosis. T2 - a systematic review and meta-analysis. AU - Liou, Kevin. AU - Jepson, Nigel. AU - Cao, Christopher. AU - Luo, Roger. AU - Pala, Sarvpreet. AU - Ooi, Sze-Yuan. PY - 2016/12. Y1 - 2016/12. N2 - Background In-stent restenosis (ISR) remains a significant mode of stent failure following PCI. The optimal treatment strategy, however, remains undefined and the role of drug-eluting balloons (DEB) in the management of ISR is also unclear.Methods A meta-analysis was performed to compare the efficacy of DEB in the treatment of ISR against second generation drug eluting stents (DES).Results Seven studies comprised of 1,065 patients were included for analysis. The follow-up period ranged from 12-25 months. The use of DEB was associated with an inferior acute gain in minimal luminal diameter (MLD) (0.36, 95% CI: 0.16-0.57 mm), higher late loss in MLD (0.11, 0.02-0.19 mm) and a higher ...

Research Report on Global Drug-Eluting Stents Market Research Report 2016. The Report includes market price, demand, trends, size, Share, Growth, Forecast, Analysis & Overview.

Registry Analysis Published in Journal Heart Finds Taxus StentImplan... ...MIAMI LAKES Fla. June 4 2007 /PRNewswire via COMTEX NewsNetwork/ -...The authors of the analysis sought to identify risk factors forsympto... The major new finding of this study was that the use of theTaxus Ste...,New,Study,Suggests,Better,Patient,Outcomes,with,CYPHER,Sirolimus-Eluting,Coronary,Stent,than,with,Taxus,Stent,in,Real-World,Clinical,Settings,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health

The FAIR trials objective was to assess safety and efficacy of angioplasty with drug-eluting balloon vs. standard angioplasty for the treatment of symptomatic superficial femoral artery in-stent restenosis. The primary endpoint was binary (≥50%) restenosis rate at six months as assessed by duplex ultrasound corelab adjudication (PSVR≥2.4). The secondary endpoints were primary angiographic success (,50% residual stenosis), six-month recurrent in-stent restenosis (≥70%) and 12-month recurrent in-stent restenosis (≥50%), six- and 12-month clinically-driven target lesion revascularisation, and clinical/haemodynamic assessment (walking distance, ankle brachial index, Rutherford category) at one, six and 12 months. The investigators also assessed the major adverse vascular events (MAVE) at 12 months.. Patients who had Rutherford class 2-4 lesions and superficial femoral artery in-stent restenosis between 70-100% as assessed by duplex ultrasound were included. Further, to be included, patients ...

AIMS: To provide insight on the patients with long lesions that received multiple, overlapping stents by reporting clinical outcomes, together with a detailed angiographic and intravascular ultrasound analysis of the overlap zone. METHODS AND RESULTS: TAXUS VI is a prospective, multicentre, double-blind, trial, specifically designed to assess outcomes of paclitaxel-eluting stents in longer lesions by randomising 446 patients (1:1) between a drug-eluting TAXUS Express2 Moderate Release (MR) and an uncoated Express2 control stent. Multiple overlapping stents were implanted in 124 patients (27.8%) and are the subject of this report. Clinical, angiographic and IVUS outcomes at nine months were compared in the overlap group for patients receiving the TAXUS Express2 MR stent and the uncoated Express2 stent. In the overlap group, mean lesion length was 25.1 mm with a mean stent length of 43.6 mm. At nine months, TVR was reduced by 94% from 25.0% to 1.6% in the TAXUS patients compared with control (p=|0.0001);

Bare metal stents: Bare metal stents (BMS) are thin spring like structures used to scaffold a blood vessel after angioplasty (removal of blocks). Bare metal stents are made of stainless steel, nitinol or cobalt-chromium.. ...

TY - JOUR. T1 - Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease. T2 - 5-Year Results From the PLATINUM Trial. AU - Kelly, Christopher R.. AU - Teirstein, Paul S.. AU - Meredith, Ian T.. AU - Farah, Bruno. AU - Dubois, Christophe L.. AU - Feldman, Robert L.. AU - Dens, Joseph. AU - Hagiwara, Nobuhisa. AU - Rabinowitz, Abram. AU - Carrié, Didier. AU - Pompili, Vincent. AU - Bouchard, Alain. AU - Saito, Shigeru. AU - Allocco, Dominic J.. AU - Dawkins, Keith D.. AU - Stone, Gregg W.. PY - 2017/12/11. Y1 - 2017/12/11. N2 - Objectives The authors sought to evaluate the final 5-year safety and effectiveness of the platinum-chromium everolimus-eluting stent (PtCr-EES) in the randomized trial, as well as in 2 single-arm substudies that evaluated PtCr-EES in small vessels (diameter ,2.5 mm; n = 94) and long lesions (24 to 34 mm; n = 102). Background In the multicenter, randomized PLATINUM (PLATINUM Clinical Trial to Assess the PROMUS Element Stent ...

Sep 28, 2015. MAJESTIC Trial Data Support Strong Safety Profile with Low Target Lesion Revascularization Rate. New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System reflect a primary patency rate1 of more than 96 percent. These results represent the highest 12-month primary patency reported for an interventional treatment of femoropopliteal artery lesions among comparable trials. The Eluvia Stent System is an advanced treatment option for patients with narrowing or blockages in the superficial femoral artery (SFA) or proximal popliteal artery (PPA), a result of peripheral artery disease (PAD).. Results from the MAJESTIC trial, which were presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting in Lisbon, Portugal, also included a low 12-month target lesion revascularization (TLR) rate of 3.8 percent, with no observed stent fractures and no ...

array(2) { [153359]=> object(eZ\Publish\Core\Repository\Values\Content\Content)#5367 (3) { [fields:protected]=> array(42) { [title]=> array(1) { [eng-GB]=> object(eZ\Publish\Core\FieldType\TextLine\Value)#5358 (1) { [text]=> string(146) Biodegradable polymer Everolimus-eluting SYNERGY stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial } } [url_title]=> array(1) { [eng-GB]=> object(eZ\Publish\Core\FieldType\TextLine\Value)#5356 (1) { [text]=> string(38) SENIOR a randomised single-blind trial } } [visibility_date]=> array(1) { [eng-GB]=> object(eZ\Publish\Core\FieldType\Date\Value)#5354 (2) { [date]=> NULL [stringFormat]=> string(7) l d F Y } } [meta_title]=> array(1) { [eng-GB]=> object(eZ\Publish\Core\FieldType\TextLine\Value)#5352 (1) { [text]=> string(146) Biodegradable polymer Everolimus-eluting SYNERGY stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial } } ...

OBJECTIVES The aim of the present study was to evaluate vascular healing of the bioengineered COMBO Dual Therapy Stent compared with a cobalt-chromium (CoCr) everolimus-eluting stent (EES) as assessed by optical coherence tomography in patients with acute coronary syndromes. BACKGROUND CD34+ cells promote endothelial repair after vascular injury. The bioengineered COMBO Dual Therapy Stent combines CD34+ cell-capturing technology with abluminal sirolimus release, but more data from clinical studies evaluating the vascular response are needed. METHODS In a prospective randomized multicenter clinical trial, 60 patients with acute coronary syndromes were randomized 1:1 to COMBO or CoCr EES implantation. The primary endpoint was the percentage of uncovered stent struts per stent. Stent assessment by optical coherence tomography was performed at baseline and at 60 days, followed by independent core laboratory analysis. RESULTS The percentage of uncovered struts per stent was higher with the COMBO than ...

The Promus ELITE Stent System builds on the proven outcomes of almost 10,000 patients in 11 clinical trials of permanent polymer coronary stents

Be informed that , National Pharmaceuticals Pricing Authority (NPPA) vide notification bearing number SO NO 412(E) dated 13th February 2017 has fixed a ceiling price on Bare Metal Stents and Drug Eluting Coronary Stents

1 Table of Contents. 1 Table of Contents 2. 1.1 List of Tables 4. 1.2 List of Figures 4. 2 Introduction 5. 2.1 What Is This Report About? 5. 2.2 Non-Vascular Stents Market Segmentation 5. 2.3 Definitions of Markets Covered in the Report 6. 3 Non-Vascular Stents Market, India 8. 3.1 Non-Vascular Stents Market, India, Revenue ($m), 2009-2016 8. 3.2 Non-Vascular Stents Market, India, Revenue ($m), 2016-2023 10. 3.2.1 Airway Stents Market, India, Revenue ($m), by Segment, 2009-2016 12. 3.2.2 Enteral Stents Market, India, Revenue ($m), by Segment, 2009-2016 14. 3.2.3 Pancreatic and Biliary Stents Market, India, Revenue ($m), by Segment, 2009-2016 16. 3.2.4 Urinary Tract Stents Market, India, Revenue ($m), by Segment, 2009-2016 18. 3.2.5 Airway Stents Market, India, Revenue ($m), by Segment, 2016-2023 20. 3.2.6 Enteral Stents Market, India, Revenue ($m), by Segment, 2016-2023 22. 3.2.7 Pancreatic and Biliary Stents Market, India, Revenue ($m), by Segment, 2016-2023 24. 3.2.8 Urinary Tract Stents ...

by Physicians Weekly , Dec 28, 2010. The 37th annual Veith Symposium was held from November 17 to 21 in New York City. The features below highlight some of the news emerging from the meeting. Analyzing Different Stenting Approaches for Restenosis The Particulars: Few studies have compared the use of drug-eluting stents after angioplasty with balloon angioplasty and bare-metal stenting in the treatment of restenosis. The Zilver PTX (Cook Medical, Inc.) is the first drug-eluting stent approved for the superficial femoral artery and is currently under investigation in the United States for use in restenosis. Researchers conducted a study comparing the Zilver PTX drug-eluting stent after angioplasty with balloon angioplasty and bare-metal stenting. Data Breakdown: The study enrolled 479 patients at 56 institutions in the United States, Japan, and Germany, with 241 patients randomized to the Zilver PTX group and 238 to the bare-metal stenting group. Demographics and lesion characteristics were ...

Research Report on Global Self-Apposing Drug-Eluting Stent Market Research Report 2016. The Report includes market price, demand, trends, size, Share, Growth, Forecast, Analysis & Overview.

In-stent restenosis has long remained the major limitation of coronary stenting. Recent randomized trials have shown that the use of drug-eluting stents (DES) markedly reduce the risk of in-stent restenosis following treatment of de novo lesions,1-4 even lesions at high risk for in-stent restenosis.5,6 Calcified lesions are often undilatable with conventional balloons and are a predictor of late in-stent thrombosis.7 Stent underexpansion is also associated with restenosis8 and in-stent thrombosis after successful DES implantati

January 8, 2018 -- The DAPT-STEMI trial, presented at the November Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting in Denver, showed the two-year patient outcomes of STEMI patients treated with the Resolute Integrity Drug-Eluting Stent, randomized to six or 12 months of dual antiplatelet therapy (DAPT). The data was presented by Dr. Elvin Kedhi, MD, PhD of Isala Hartcentrum in Zwolle, the Netherlands. The result: after two years, there was no significant difference in the primary or secondary endpoints between the standard 12 month regimen of DAPT and the shortened duration. This is reassuring news for physicians and patients since, although 12 months is currently the recommended duration for DAPT after primary PCI for STEMI, a large number of patients prematurely discontinue DAPT. In fact the RESOLUTE Pooled Analysis of 5,000 patients showed that 1 in 6 stopped taking clopidogrel, prasugrel, or ticagrelor (plus aspirin) in the first few months after stenting. There are a number ...

News and information on minimally invasive coronary disease therapies, covering valvular, structural, radial access, chronic total occlusion, and imaging issues.

In medicine, a stent is any device which is inserted into a blood vessel or other internal duct in order to expand the vessel to prevent or alleviate a blockage. Traditionally, such devices are fabricated from metal mesh and remain in the body permanently or until removed through further surgical intervention. A bioresorbable stent, (also called biodegradable, or naturally-dissolving) serves the same purpose, but is manufactured from a material that may dissolve or be absorbed in the body. The use of metal drug-eluting stents presents some potential drawbacks. These include a predisposition to late stent thrombosis, prevention of late vessel adaptive or expansive remodeling, hindrance of surgical revascularization, and impairment of imaging with multislice CT. To overcome some of these potential drawbacks, several companies are pursuing the development of bioresorbable or bioabsorbable stents. Like metal stents, placement of a bioresorbable stent will restore blood flow and support the vessel ...

New York, NY - March 29, 2016 - Physicians and fellows from the Cardiovascular Research Foundation (CRF) will be presenting abstracts at the American College of Cardiology 65th Annual Scientific Session taking place April 2-4, 2016 at McCormick Place in Chicago, IL. They will be sharing the latest data on drug-eluting stents, imaging technologies, dual antiplatelet therapy, transcatheter aortic valve replacement, and bioresorbable vascular scaffolds.. CRF will also host a satellite program on complex PCI prior to the start of ACC on Friday, April 1, 6:30 PM - 9:00 PM called CHIP: The Interventional Toolbox for Complex Higher-Risk (and Indicated) Patients at the Loews Chicago Hotel (Wright Ballroom, First Floor). Presentations will address treatment of left main disease, chronic total occlusions, long lesions, bifurcation lesions, small vessels, and saphenous vein grafts. Expert faculty will offer insights into selecting devices and patients, optimizing technique, and overcoming difficult ...

Drug-eluting stents (DES) are used by interventional cardiologists, operating on patients with coronary artery disease. The stent is inserted into the artery via a balloon angioplasty. This will dilate the diameter of the coronary artery and keep it fixed in this phase so that more blood flows through the artery without the risk of blood clots (atherosclerosis).[6] Phosphorylcholine is used as the polymer-based coating of a DES because its molecular design improves surface biocompatibility and lowers the risk of causing inflammation or thrombosis. Polymer coatings of stents that deliver the anti-proliferative drug Zotarolimus to the arterial vessel wall are key components of these revolutionary medical devices. For targeted local delivery of Zotarolimus to the artery, the drug is incorporated into a methacrylate-based copolymer that includes a synthetic form of phosphorylcholine. This use of biomimicry, or the practice of using polymers that occur naturally in biology, provides a coating, with ...

Objective: Drug-eluting stents (DES) have reduced restenosis rates compared with bare-metal stents. P27 and P53 play important roles in the signal transduction leading to neointimal growth inhibition and induction of apoptosis of smooth muscle cells due to rapamycin and paclitaxel. We hypothesized that genetic variants of P27 and P53 influence the development of restenosis and the clinical outcome of patients receiving DES. Methods: Polymorphisms in the genes encoding for P27 and P53 were tested for their association with restenosis and major adverse cardiac events. P27 C-79T and P53 G72C polymorphism genotypes were determined in a series of 433 consecutive patients receiving DES. Follow-up angiography after 6 months was performed in 87% of the patients. Genotyping was performed with PCR-based methods. Results: For patients with the respective P27 C-79T and P53 G72C genotypes, the angiographic restenosis rates were between 5.0 and 22.0%, and the clinical restenosis rates were between 0.0 and ...